Drugs / AZD6234
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07546760 | Mar 2026 → Feb 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07220954 | Nov 2025 → Sep 2026 overdue | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07013643 | Jun 2025 → Jul 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06845813 | Feb → Sep 2025 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06132841 | Nov 2023 → Feb 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05511025 | Sep 2022 → Dec 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06151964 | Sep 2023 → Jan 2027 expected | morbid obesity | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07017179 | May 2025 → Oct 2026 expected | obesity disorder | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06851858 | Mar 2025 → May 2026 | obesity disorder, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT06862791 | Feb 2025 → May 2026 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT06595238 | Oct 2024 → Dec 2025 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07784270 | Aug 2026 → Aug 2028 expected | obesity disorder, type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06862791 ↗ |
| Modality | Small activating RNA (saRNA) | “AZD6234, a SARA, for the treatment of overweight and obesity” NCT06151964 ↗ |
| Route | Intravenous | “via SC or IV injection” NCT05511025 ↗ |
| Route | Subcutaneous | “via SC or IV injection” NCT05511025 ↗ |